SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Genitourinary Oncology
Prognostic value of platelet to lymphocyte ratio in patients with castration-resistant prostate cancer: a systematic review and meta-analysis
Provisionally accepted
- Dongyang People’s Hospital, Dongyang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Although the platelet-to-lymphocyte ratio (PLR) has been identified as a prognostic marker in various cancers, its role in castration-resistant prostate cancer (CRPC) remains uncertain. This meta-analysis examines the prognostic significance of PLR in relation to overall survival (OS) and progression-free survival (PFS) in patients with CRPC. We systematically searched PubMed, Embase, Web of Science, and the Cochrane Library up to March 11, 2025. Two reviewers independently screened studies, extracted data, and assessed quality using the Newcastle–Ottawa Scale (NOS). Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Sensitivity and subgroup analyses explored heterogeneity and assessed result stability. All analyses were performed using Review Manager 5.4 and STATA 15.0. A total of 13 studies (14 comparison groups; 2,405 patients) were included. High PLR was significantly associated with shorter OS (HR = 1.62, 95% CI: 1.30-2.03), but not with PFS (HR = 1.25, 95% CI: 0.92-1.69). Subgroup analyses confirmed the association with poor OS in prospective studies, patients aged ≥72, European populations, those on hormone therapy, and studies using a PLR cut-off ≥150. Heterogeneity mainly arose from differences in study design, treatment, and region. Sensitivity analyses and Egger’s test confirmed the robustness of findings with no publication bias. PLR is a significant predictor of OS in CRPC and may help guide clinical risk stratification. However, its role in predicting PFS is limited. Further prospective studies are needed to validate its clinical utility.
Keywords: castration-resistant prostate cancer, platelet-to-lymphocyte ratio, prognosis, overall survival, Progression-free survival
Received: 28 Jun 2025; Accepted: 21 Nov 2025.
Copyright: © 2025 Ying, Zhou and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Junhui Ying, yjh20021999@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.